Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Conventional Chondrosarcoma
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Beverly Hospital, Beverly, Massachusetts
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
NCT04047251
Recruiting
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute (DFCI), Boston, Massachusetts
Conditions: Advanced Solid Tumors, Merkel Cell Carcinoma
Register for Updates
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
NCT03709758
Recruiting
This research study is studying the combination of venetoclax and chemotherapy as a possible treatment for acute myelogenous leukemia (AML). The drugs involved in this study are: * Venetoclax * Daunorubicin * Cytarabine
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/09/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
NCT06773195
Recruiting
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in participants when given in combination with ruxolitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts
Conditions: Myelofibrosis
Register for Updates
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
NCT06562270
Recruiting
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers. Visit schedules for patients will be determined by the provider in accordance with routine clinical care, and any prescriptions provided to patients will adhere to product availability and local prescribing guidelines/regulations in the country where the participating registry site is located.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
01/08/2025
Locations: CorEvitas, LLC, Waltham, Massachusetts
Conditions: Alopecia Areata
Register for Updates
Non-invasive Point-Of-Care Hemoglobin Testing In An Obstetric Population
NCT06521840
Recruiting
Anemia is common during pregnancy due to increased metabolic rate and normal physiologic changes associated with pregnancy. Anemia during pregnancy has been associated with increased of adverse outcomes during delivery and the postpartum period. Currently, it is recommended to screen for anemia at three pre-specified points during routine prenatal care, typically 3 months apart. This screening method may miss patients who develop anemia between these intervals and lead to a delay in diagnosis an... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
01/08/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Pregnancy Anemia
Register for Updates
Testimonials and Navigation in Rheumatology
NCT06469788
Recruiting
The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Brigham Women's Hospital, Boston, Massachusetts
Conditions: Rheumatologic Disease, Autoimmune Diseases
Register for Updates
CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
NCT06238765
Recruiting
Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.
Gender:
ALL
Ages:
Between 12 years and 15 years
Trial Updated:
01/08/2025
Locations: CorEvitas, LLC, Waltham, Massachusetts
Conditions: Atopic Dermatitis
Register for Updates
Validation of a Novel Cerebellar-striatal Satiety Circuit in Humans
NCT06105164
Recruiting
This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study satiety in healthy individuals. TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study, the investigators will be stimulating the brain to learn more about the role of the cerebellum in satiety.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/08/2025
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Appetitive Behavior, Obesity
Register for Updates
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05986864
Recruiting
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/08/2025
Locations: Ophthalmic Consultants of Boston, Boston, Massachusetts
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Just-in-time Interventions for Reducing Short-term Suicide Risk
NCT05793541
Recruiting
The goal of this study is to test the effects of just-in-time intervention strategies aimed to promote implementation of the safety plan and its components at different levels of suicidal urges and intent. The main questions the investigators aim to answer are: 1. What is the acceptability and feasibility of the just-in-time intervention strategies? 2. What are the proximal effects of just-in-time intervention strategies aimed to promote use of the safety plan and its components? 3. What intern... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Mass General Brigham, Boston, Massachusetts
Conditions: Suicide
Register for Updates